Core Points - The Shanghai Composite Index opened lower and the CSI 300 Pharmaceutical and Biotechnology Index reported 7479.61 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has decreased by 0.64% in the past month, increased by 3.66% over the last three months, and has risen by 0.48% year-to-date [1] Industry Composition - The CSI 300 Pharmaceutical and Biotechnology Index is composed of 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] - The index is based on the performance of all securities in the CSI 300 Index classified by industry, with a base date of December 31, 2004, and a base point of 1000.0 [1] Index Holdings - The top ten holdings in the CSI 300 Pharmaceutical and Biotechnology Index are: - Heng Rui Medicine (24.75%) - WuXi AppTec (15.82%) - Pian Zai Huang (6.85%) - Yunnan Baiyao (5.7%) - Kelun Pharmaceutical (4.68%) - New Horizon (3.79%) - East China Pharmaceutical (3.64%) - Shanghai Raist (3.44%) - Fosun Pharma (3.38%) - Changchun High-tech (3.17%) [1] Market Distribution - The market distribution of the CSI 300 Pharmaceutical and Biotechnology Index shows that the Shanghai Stock Exchange accounts for 63.33% and the Shenzhen Stock Exchange accounts for 36.67% [2] Sector Breakdown - The sector breakdown of the index holdings indicates that: - Chemical drugs account for 42.69% - Pharmaceutical and biotechnology services account for 21.06% - Traditional Chinese medicine accounts for 19.74% - Biological drugs account for 16.51% [2] Sample Adjustment - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with sample changes, and any special events affecting a sample company's industry classification will lead to corresponding adjustments in the index [2]

Group 1: Investment and Growth Strategy - The company plans to optimize its industrial portfolio through both "internal" and "external" collaborative development, focusing on strategic mergers and partnerships to overcome growth bottlenecks and achieve sustainable development [2][3]. Group 2: Pharmaceutical Business Performance - In 2024, the pharmaceutical segment achieved significant growth by positioning itself as the "leading brand in comprehensive pain management," enhancing product visibility and ecosystem through clinical research and marketing strategies [4][5]. - The pharmaceutical group reported steady progress in clinical studies for various products, including those targeting diabetic foot and bone pain, contributing to broader application scenarios [4]. Group 3: Traditional Chinese Medicine (TCM) Supply Chain Development - The company is committed to developing a world-class modern TCM industry, with initiatives in seed cultivation, planting, processing, and branding, including the establishment of a specialized seed company [6][7]. - In 2024, the company reported a 180% increase in the production of fresh medicinal materials and a 182% increase in food and health product output, supporting high-quality development [6]. Group 4: Health Products Performance - The health product segment, particularly the Yangyuanqing hair care line, achieved sales revenue of 422 million yuan in 2024, marking a 30.3% year-on-year growth [8]. Group 5: Nuclear Medicine R&D Progress - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024, with promising results indicating excellent stability and safety [9][11]. Group 6: Health Product Channel Development - The company maintains a comprehensive national sales team for health products, with a leading market share in oral care products, and is optimizing both traditional and emerging sales channels [12]. Group 7: Digital Transformation Initiatives - The company is implementing a digital development plan (2022-2026) that leverages AI and data to enhance all aspects of the supply chain, aiming for a smart and green transformation in the TCM industry [13][14]. Group 8: Provincial Pharmaceutical Company Performance - The provincial pharmaceutical company achieved a main business revenue of 24.607 billion yuan in 2024, with a 0.48% year-on-year growth, and significant increases in non-pharmaceutical business sales [15][16].

云南白药集团股份有限公司 投资者调研会议记录表 1 / 2 | | 药品事业群总经理-郑祥伟 | | --- | --- | | | 健康品事业群总经理-黄玉敏 | | | 中药资源事业群总经理-李春平 | | | 省医药有限公司总经理-朱家龙 | | | 证券事务代表-李孟珏 | | | 投资者关系管理-杨可欣 | | 投资者关系活动主要 | 了解公司生产经营情况等相关问题 | | 内容介绍 | | | 附件清单 | 会议记录 | 2 / 2 编号：20-2504-15 | | ☑特定对象调研 | □分析师会议 | | --- | --- | --- | | | □媒体采访 | □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | □路演活动 | | | ☑现场参观 | □一对一沟通 | | | □其他（电话会议） | | | 参与单位名称及人员 | 中信证券-陈竹、刘晓岚、宋硕、李文涛 | | | | 中信建投-刘若飞、沈兴熙 | | | | 国泰海通-张澄、唐玉青 | | | | 华泰证券-张云逸 | | | | 富国基金-黄致君 | | | 姓名 | 大成基金-王敏杰 | | | | 泰康资 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及其董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 云南白药集团股份有限公司（以下简称"公司"或"本公司"）2024年度权益分派方案已获2025年4月21日 召开的公司2024年度股东大会审议通过，股东大会决议公告刊登于2025年4月22日的《中国证券报》 《上海证券报》《证券时报》及巨潮资讯网（http://www.cninfo.com.cn）。 一、股东大会审议通过权益分派方案情况 1、本公司获股东大会审议通过的2024年度权益分派具体方案为：以公司现有总股本1,784,262,603股为 基数，向全体股东每10股派发现金红利11.85元（含税），送红股0股，不以资本公积金转增股本，本次 现金分红总金额2,114,351,184.56元。按照本方案分配比例，以分配方案未来实施时股权登记日享有利润 分配权利的股份数量为基数，从而最终确定分配总额。其余未分配利润留待以后年度分配。在公司利润 分配预案披露之日起至实施权益分派股权登记日期间，公司享有利润分配权的股份总额由于增发新股、 股权激励行权、可转债转股、股份回 ...

1 Topic Steady Progress with Legacy of Baiyao Innovation-driven Exploration of New Horizons in TCM Green Development for Deepening Ecological Civilization People First for Strengthening the Foundation of Talent Cultivating Virtue and Embracing Responsibilities Appendix Feedback Form | Leadership in Party Building | 27 | | --- | --- | | Operation of the Board of Directors | 29 | | Risk Management | 31 | | Business Ethics | 33 | | Product Quality | 37 | | --- | --- | | R&D Innovation | 41 | | Customer Service ...

股票代码：000538 股票简称：云南白药 公告编号：2025-16 2、公司已于 2024 年 11 月完成 2024 年特别分红利润分派，每 10 股派送 现金 12.13 元（含税），现金分红金额共计 2,164,310,537.44 元（含税）。本 次拟实施的现金分红总金额 2,114,351,184.56 元，与 2024 年已实施的特别分 红合并计算，以 2024 年末公司总股本 1,784,262,603 股为基数，2024 年度每 10股累计派送现金23.98 元（含税），累计现金红利总额合计为4,278,661,722.00 元（含税），占 2024 年度公司归属于上市公司股东净利润的 90.09%。 1 / 3 3、本次实施的权益分派方案与股东大会审议通过的权益分派方案一致。 4、本次实施权益分派方案距离股东大会审议通过的时间没有超过两个月。 云南白药集团股份有限公司 2024 年度权益分派实施公告 本公司及其董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 云南白药集团股份有限公司（以下简称"公司"或"本公司"）2024 年度权 益分派方案已获 2 ...

股票代码：000538 股票简称：云南白药 公告编号：2025-15 云南白药集团股份有限公司 2024年度股东大会决议公告 重要提示：本公司及董事会全体成员保证信息披露内容的真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 重要提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更前次股东大会决议。 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： 1、股东出席的总体情况： （1）现场会议召开时间：2025 年 4 月 21 日上午 9:30。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的 时间为 2025 年 4 月 21 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深 圳证券交易所互联网投票系统投票的时间为 2025 年 4 月 21 日 9:15-15:00。 2、现场会议召开地点：云南省昆明市呈贡区云南白药街 3686 号云 南白药集团股份有限公司总部白药空间二楼会议室。 3、会议召开方式：本次股东大会以现场表决和网络投票相结合的方 式召开。公司将通过深圳证券交易所交易系统和互联网投票系统 1 / 7 （http ...

关于云南白药集团股份有限公司 北京德恒（昆明）律师事务所 2024 年度股东大会的 法律意见 北京德恒（昆明）律师事务所 Beijing DeHeng Law Offices (KunMing) 云南省昆明市西山区西园路 126 号"融城优郡"B5 幢 3、4 层 电话（传真）：0871-63172192 邮编:650032 北京德恒（昆明）律师事务所 关于云南白药集团股份有限公司 2024 年度股东大会的 根据公司提供的有关资料及公开披露的信息，表明公司董事会已于 2025 年 3 月 31 日召开了会议，作出了关于召开本次股东大会的决议，并于 2025 年 3 月 31 日在《中国证券报》《证券时报》《上海证券报》和巨潮资讯网站等媒体刊登 了召开本次股东大会的通知。 本次股东大会于 2025 年 4 月 21 日 9:30 在昆明市呈贡区云南白药街 3686 号 云南白药集团股份有限公司白药空间二楼会议室召开，会议召开时间与通知公告 时间间隔 20 天以上，会议召开的具体时间、地点和审议事项也与公告内容一致。 本次股东大会由公司董事长张文学主持，符合法律、法规及《公司章程》的 规定。 二、关于出席本次股东 ...

Group 1: Overall Financial Performance - In 2024, the company achieved a revenue of 40.033 billion CNY, a year-on-year increase of 2.36% [2] - The net profit attributable to shareholders reached 4.749 billion CNY, up 16.02% from 4.094 billion CNY in the previous year [2] - The non-recurring net profit was 4.523 billion CNY, reflecting a 20.18% increase compared to 3.764 billion CNY last year, marking a historical high [2] Group 2: Growth Quality Indicators - Operating cash flow net amount was 4.297 billion CNY, a growth of 22.68% year-on-year [3] - The weighted average return on equity was 11.99%, an increase of 1.48 percentage points from the previous year [3] - Basic earnings per share were 2.66 CNY, representing a 16.16% increase compared to the previous year [3] Group 3: Cost Management and Efficiency - Sales expenses decreased by 2.26% year-on-year, while management expenses dropped by 1.98% [3] - The industrial revenue accounted for 36.14% of total revenue, with an industrial revenue growth rate of 5.30% [3] - The industrial gross profit margin was 65.93%, an increase of 1.69 percentage points from the previous year [3] Group 4: Asset Structure - As of the end of the reporting period, total assets were 52.914 billion CNY, with net assets attributable to shareholders at 38.832 billion CNY [4] - The debt-to-asset ratio stood at 26.55%, with cash and cash equivalents amounting to 10.888 billion CNY [4] Group 5: Pharmaceutical Business Growth - The pharmaceutical segment focused on becoming the "first brand" in pain management, enhancing product visibility and ecosystem [5] - Clinical research on core products showed steady progress, expanding application scenarios [5] - Marketing initiatives successfully targeted younger demographics, leading to increased product penetration [5] Group 6: Raw Material Cost Control - The Chinese medicine resource segment managed to keep raw material price increases below the industry average [6] - A "big procurement" integrated management platform led to a cost reduction of 31 million CNY [6] - The establishment of a digital ecosystem for traditional Chinese medicine improved supply chain efficiency [6] Group 7: Nuclear Medicine Development - The INR101 diagnostic nuclear medicine project received clinical approval in May 2024, with promising stability and safety results [7] - The INR102 injection for treating advanced prostate cancer has received approval for clinical trials [7]

云南白药集团股份有限公司 投资者调研会议记录表 | 投资者关系活动类别 | □特定对象调研 | | □分析师会议 | | --- | --- | --- | --- | | | □媒体采访 | | □业绩说明会 | | | □新闻发布会 | | □路演活动 | | | □现场参观 | | □一对一沟通 | | | ☑ 其他（电话会议） | | | | 参与单位名称及人员 | 大家资产-胡筱、吴斌 | | | | 姓名 | 长盛基金-李雨辰、洪靖怡 | | | | | 国联证券-陈翠琼 | | | | 时间 | 2025 年 4 17 日星期四 | 月 | | | 地点 | 集团总部办公大楼 | | | | 上市公司接待人员 | 证券事务代表-李孟珏，投资者关系管理-杨可欣 | | | | 投资者关系活动主要 | 了解公司生产经营情况等相关问题 | | | | 内容介绍 | | | | | 附件清单 | 会议记录 | | | 1 / 1 编号：19-2504-14 ...